Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. ECCMID 2018: Avycaz set for paediatric label expansion following Phase IIb trials
  2. Completion of THX-110 trial marks a step forward for medical cannabis development
  3. AACR 2018: SLFN11 predicts response to PARP inhibition in small cell lung cancer
  4. TaiwanJ’s JKB-121 falls victim to unexpected placebo response in NASH patients
  5. ILC 2018: NGM’s intravenous NASH therapy shows rapid reduction in liver fat content and fibrosis

Latest Content

Completion of THX-110 trial marks a step forward for medical cannabis development

Therapix Biosciences, a biopharmaceutical company focused on the development of cannabinoid-based treatments, reported topline data on April 9th from a Phase IIa study at Yale University showing that its cannabinoid-based treatment, THX-110, met its primary endpoint for Tourette syndrome (TS). THX-110, which is a combination drug of dronabinol (THC) and palmitoylethanolamide (PEA), significantly improved symptoms in adult subjects with the disorder.

Summit Therapeutics ends dosing in PhaseOut DMD trial

Summit Therapeutics has completed patient dosing in the PhaseOut DMD clinical trial, a Phase II study of ezutromid to treat patients with duchenne muscular dystrophy (DMD), the most common and severe form of muscular dystrophy.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top